Oncogenic KRAS mutations are a hallmark of cancer, being a very frequent event in many cancers, including pancreatic cancers (90%), CRCs (30–50%) and lung cancers, especially non-small-cell lung cancer (NSCLC) (15–20%). Here, KRAS is linked to non-small cell lung carcinoma.